S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
TSE:HBP

Helix BioPharma (HBP) Stock Price, News & Analysis

C$0.18
0.00 (0.00%)
(As of 03/28/2024 04:30 PM ET)
Today's Range
C$0.18
C$0.18
50-Day Range
C$0.17
C$0.22
52-Week Range
C$0.15
C$0.26
Volume
14,017 shs
Average Volume
16,812 shs
Market Capitalization
C$39.00 million
P/E Ratio
N/A
Dividend Yield
1.50%
Price Target
N/A
HBP stock logo

About Helix BioPharma Stock (TSE:HBP)

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.

HBP Stock Price History

HBP Stock News Headlines

Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Helix Biopharma GAAP EPS of -C$0.01
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Helix BioPharma Corp.: Helix Announces Board Resignation
See More Headlines
Receive HBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Helix BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Next Earnings (Estimated)
4/03/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
9
Year Founded
N/A

Profitability

Net Income
C$-5,940,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
C$39.00 million
Optionable
Not Optionable
Beta
-0.71
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. Jacek Antas
    Chairman & CEO
  • Mr. Praveen Kumar Varshney F.C.A. (Age 58)
    FCA, FCPA, LLB, CFO & Corporate Secretary
  • Dr. Gabrielle M. Siegers M.A.
    Ph.D., Head of R&D
  • Dr. Srikanth Sola
    Chief Strategy Officer
  • Dr. Christof Boehler
    Chief Business Development Officer

HBP Stock Analysis - Frequently Asked Questions

How have HBP shares performed in 2024?

Helix BioPharma's stock was trading at C$0.21 at the beginning of 2024. Since then, HBP stock has decreased by 14.3% and is now trading at C$0.18.
View the best growth stocks for 2024 here
.

When is Helix BioPharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024.
View our HBP earnings forecast
.

What other stocks do shareholders of Helix BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Helix BioPharma investors own include Lakeland Industries (LAKE), Liquidia (LQDA), Ovintiv (OVV), SIG (SHI), Green Organic Dutchman (TGOD), Zynerba Pharmaceuticals (ZYNE), American Airlines Group (AAL), Aurora Cannabis (ACB), Apollo Investment (AINV) and Aphria (APHA).

How do I buy shares of Helix BioPharma?

Shares of HBP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:HBP) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners